Lin et aldonanemabAducanumablecanemabAlzheimer’s diseaseFDAADMCImild cognitive impairmentU.S. Food and Drug Administration+2 more
… cheaper, simpler to administer and safer. In their JNNP paper, Lin et al 3 address these questions by performing a systematic review and…